| The dynamic capability view in exploring the relationship between high-performance work systems and innovation performance G Mehralian, S Sheikhi, C Zatzick, J Babapour The International Journal of Human Resource Management 34 (18), 3555-3584, 2023 | 25 | 2023 |
| Diabetic Patients’ Views on Services Provided by Community Pharmacies G Mehralian, S Sheikhi, F Peiravian Journal of Pharmaceutical Health Services Research 9 (4), 335-340, 2018 | 4 | 2018 |
| High-Performance Work Systems and Innovation Performance Link: How Dynamic Capabilities Mediate S Sheikhi, CD Zatzick, H Heidarian Ghaleh, G Mehralian Academy of Management Proceedings 2022 (1), 14268, 2022 | 3 | 2022 |
| Evaluation of pharmaceutical system responsiveness to non-therapeutic needs of patients using WHO framework: The case of Tehran's outpatient pharmacies S Sheikhi, S Taheri, N Yousefi, F Peiravian Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) 2, 44-9, 2018 | 2 | 2018 |
| Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran M Ekhlasi, S Sheikhi, ZK Majd, F Peiravian, N Yousefi Value in Health Regional Issues 34, 78-85, 2023 | 1 | 2023 |
| The Mediating Role of Organizational Identification on Sustainable Human Resources Management and Organizational Citizenship Behavior’s Relationship S Sheikhi, N Yousefi Iranian Journal of Pharmaceutical Research: IJPR 22 (1), 2023 | | 2023 |
| COST-MINIMIZATION ANALYSIS OF INSULIN LISPRO 50/50 VERSUS INSULIN ASPART 30/70 PREMIXED FORMULATIONS IN TYPE II DIABETES N Yousefi, S Taheri, S Sheikhi, B Amani, A Akbarzadeh, F Peiravian ISPOR Europe 2019, 2019 | | 2019 |
| COST-EFFECTIVENESS ANALYSIS OF TOPOTECAN IN COMPARISON WITH PACLITAXEL AS SECOND-LINE CHEMOTHERAPY IN THE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER IN IRAN N Shobeiri, S Taheri, S Sheikhi, F Peiravian ISPOR Europe 2019, 2019 | | 2019 |
| PDB12 COST-MINIMIZATION ANALYSIS OF INSULIN LISPRO 50/50 VERSUS INSULIN ASPART 30/70 PREMIXED FORMULATIONS IN TYPE II DIABETES N Yousefi, S Taheri, S Sheikhi, B Amani, A Akbarzadeh, F Peiravian Value in Health 22, S573-S574, 2019 | | 2019 |
| PCN212 ECONOMIC EVALUATION OF TOPOTECAN IN COMPARISON WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN THE TREATMENT OF RECURRENT OVARIAN CANCER IN IRAN S Sheikhi, S Taheri, N Shobeiri, F Peiravian Value in Health 22, S477, 2019 | | 2019 |
| PHP196-DEVELOPMENT STRATEGIES PROMOTING PHARMACEUTICAL INDUSTRY TO IMPROVE HEALTHCARE MANAGEMENT J Babapour, M Peikanpour, ZK Majd, MP Moghaddam, S Sheikhi Value in Health 21, S183, 2018 | | 2018 |
Farzad PeiravianAssociate Professor in Department of Pharmacoeconomics and Pharma Management, School of Pharmacy在 sbmu.ac.ir 的电子邮件经过验证
